The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Kinnate Biopharma
Stock and Other Ownership Interests - Kinnate Biopharma
Antitumor activity of KIN-2787, a next-generation pan-RAF inhibitor, in combination with MEK inhibition in preclinical models of human NRAS mutant melanoma.
 
Nichol Miller
Employment - Kinnate Biopharma; Pfizer
Stock and Other Ownership Interests - Kinnate Biopharma; Pfizer
Patents, Royalties, Other Intellectual Property - Kinnate BioPharma patent(s) containing intellectual property regarding its small molecule inhibitors for use in oncology treatment
 
Tim Sen Wang
Employment - Kinnate Biopharma
Stock and Other Ownership Interests - Kinnate Biopharma
 
Catherine Lee
Employment - Kinnate Biopharma; Pfizer
 
Paul Severson
Employment - Kinnate Biopharma; Plexxikon
Stock and Other Ownership Interests - Daiichi Sankyo/UCB Japan; Kinnate Biopharma
Travel, Accommodations, Expenses - Plexxikon
 
Eugene Ke
No Relationships to Disclose
 
Ken Kobayashi
Employment - Daiichi-Sankyo; Kinnate Biopharma; Pfizer
Stock and Other Ownership Interests - Daiichi Sankyo; Kinnate Biopharma; Pfizer
Patents, Royalties, Other Intellectual Property - MOU for KIN-3248
 
Richard Thomas Williams
Employment - Kinnate Biopharma
Stock and Other Ownership Interests - Kinnate Biopharma